1197 studies found for:    "multiple sclerosis"
Show Display Options
Rank Status Study
21 Not yet recruiting Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Relapsing Forms of Multiple Sclerosis
Interventions: Drug: dimethyl fumarate;   Drug: Placebo
22 Completed Bayer/Cognitive Assessments With Multiple Sclerosis Subjects
Conditions: Multiple Sclerosis, Relapsing-remitting;   Multiple Sclerosis, Secondary Progressive
Intervention:
23 Completed Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive
Intervention: Biological: Tovaxin Autologous T Cell Vaccine
24 Completed Safety of RG2077 in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: RG2077 (CTLA4-IgG4m)
25 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
26 Active, not recruiting Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases of the Nervous System;   Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Disease Progression;   Brain Atrophy
Interventions: Biological: Tcelna;   Biological: Placebo
27 Completed BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BG00012 (dimethyl fumarate);   Drug: Glatiramer Acetate;   Drug: Interferon beta 1a
28 Completed Extension Study to Evaluate Safety and Efficacy of BG00002 (Natalizumab) in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: natalizumab
29 Active, not recruiting An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: dimethyl fumarate
30 Completed Treatment of Multiple Sclerosis Using Over the Counter Inosine
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Inosine
31 Not yet recruiting Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With BG00012 or Standard of Care
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Other: Standard of Care (SOC) First Line Treatements
32 Recruiting A Study Evaluating the Effectiveness of Tecfidera™ (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate (DMF)
33 Enrolling by invitation Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BIIB019 (Daclizumab High Yield Process)
34 Active, not recruiting Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: ibudilast;   Drug: Placebo
35 Completed
Has Results
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 100;   Drug: Ofatumumab 300;   Drug: Ofatumumab 700;   Drug: Placebo
36 Withdrawn Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
37 Active, not recruiting Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Condition: Multiple Sclerosis
Intervention: Drug: Rituximab
38 Recruiting A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Rituximab
39 Completed A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
40 Completed Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Progressive Relapsing Multiple Sclerosis
Intervention: Biological: Autologous mesenchymal stem cell transplantation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years